KEY INVESTOR MESSAGES Commercial launch of Genedrive® Hepatitis C (HCV) test expected to start in the coming quarters (African markets) Collaboration with the US Defense Department (bio-hazard program) to generate further income in the current fiscal year Re-launch of Genedrive® MTB (tuberculosis) test in India is being reassessed Divestment options for the Services business are being pursued Cash position of £4.2mln as of 30 September 2017
17 Oct 2017
Genedrive - Capital Network: FY 2017 Preliminary results: HepC test launch in sight
Sign up for free to access
Get access to the latest equity research in real-time from 12 commissioned providers.
Get access to the latest equity research in real-time from 12 commissioned providers.
Genedrive - Capital Network: FY 2017 Preliminary results: HepC test launch in sight
Genedrive Plc (GDR:LON) | 5.9 0 0.0% | Mkt Cap: 8.41m
- Published:
17 Oct 2017 -
Author:
Dr. Riccardo Lowi -
Pages:
2
KEY INVESTOR MESSAGES Commercial launch of Genedrive® Hepatitis C (HCV) test expected to start in the coming quarters (African markets) Collaboration with the US Defense Department (bio-hazard program) to generate further income in the current fiscal year Re-launch of Genedrive® MTB (tuberculosis) test in India is being reassessed Divestment options for the Services business are being pursued Cash position of £4.2mln as of 30 September 2017